Improvement of Neuropsychological Function in Cognitively Impaired Multiple Sclerosis Patients Treated with Natalizumab

Edwards, Keith R.; Goodman, W.; Ma, Carl Y.

doi:10.7224/1537-2073-14.2.100

Cited by 4 publications

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A total of 15 ( 30 ) assessed parameters improved over time, 15 remained equal. These results are comparable with another sample of 40 patients with RRMS ( 31 ), treated with NTZ over 6 months. Cognitive improvements were demonstrated by using a comprehensive cognitive battery.…”

Section: Discussionsupporting

confidence: 83%

“…NTZ has positive effects on physical disabilities, in reducing the relapse rate and magnetic resonance imaging (MRI) detectable disease activity ( 29 , 30 ). Past studies investigated the effect of NTZ on cognition and partially also on depression and fatigue over the observational periods of 6 months to 1 year ( 31 – 35 ). Putzki et al ( 36 ) encompassed fatigue and depressive symptoms at baseline immediately before the treatment with NTZ and 6 months later.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Impact of Natalizumab Treatment on Fatigue, Mood, and Aspects of Cognition in Relapsingâ€“Remitting Multiple Sclerosis

et al. 2015

View full text Add to dashboard Cite

Background/objectiveFatigue, cognitive, and affective disorders are relevant symptoms in multiple sclerosis (MS). The treatment with Natalizumab has a positive effect on physical disabilities in patients with relapsing–remitting MS (RRMS). Some studies describe improvements in cognition and fatigue over 1 year of treatment. Only little is known about longer treatment effects especially on fatigue, and also on cognition and mood. Therefore, the present retrospective open label observational study investigates the effect of Natalizumab on fatigue, attention, and depression over a treatment period of 2 years.MethodsAbout 51 RRMS patients who were treated with Natalizumab (male = 11, female = 40; mean age: 33. 9 ± 9. 1 years) were included. The neuropsychological assessment consisted of different tests of attention (TAP: alertness, divided attention, flexibility, SDMT, PASAT), fatigue (WEIMuS, FSMC), and depression (CES-D). The assessments occurred immediately before the first administration of Natalizumab, after 1 and 2 years of treatment.ResultsSignificant improvements were found in aspects of attention and depression from baseline to follow-up 1 [alertness: reaction time (RT) cued, p < 0.05; divided attention: visual RT, p < 0.05; SDMT: p = 0.05; CES-D: p < 0.05] and from baseline to follow-up 2 (divided attention: visual RT: p < 0.001; errors: p < 0.01, omissions: p < 0.05; flexibility: RT, p < 0.05; SDMT: p < 0.01; CES-D: p < 0.05). No significant changes were detected in fatigue, probably because of the small sample size, especially in the second year of treatment (WEIMuS: N = 16, FSMC: N = 8).ConclusionThe results show a positive effect of Natalizumab on attention in patients with RRMS, and for the first time, also in depression after 2 years of observation, and support the efficacy of the treatment over 2 years. More research is needed for fatigue.

show abstract

Section: Discussionsupporting

confidence: 83%